NMPA (China)National Medical Products Administration

NMPA (National Medical Products Administration / 国家药品监督管理局) is the central regulator of the People's Republic of China for drugs, medical devices + cosmetics. NMPA was created in the Mar 2018 State Council reorganisation that replaced CFDA (China Food and Drug Administration), transferred food regulation to SAMR + General Administration of Customs, and kept medical-products + cosmetics regulation under NMPA, which itself sits under SAMR (State Administration for Market Regulation).

NMPA operates through a network of specialised centres + provincial Medical Products Administrations (MPAs):

• CDE — Center for Drug Evaluation (drug + biological + ATMP scientific review).
• CMDE — Center for Medical Device Evaluation (Class II + III device + IVD scientific review).
• CFDI — Center for Food and Drug Inspection (GMP + GCP + GLP + GVP inspections; CFDI inspectors are the operational arm).
• NIFDC — National Institutes for Food and Drug Control (the national reference + testing institute; Type Testing + lot release for biologicals).
• ChP Commission — Chinese Pharmacopoeia Commission (the national pharmacopoeial authority).
• NMPA Information Center + cosmetics + radiation centres + provincial MPAs (handling Class I drug functions + Class I + II device functions at provincial level).

Legal foundations are the Drug Administration Law of PRC (revised Dec 2019), the Drug Registration Regulation (NMPA Order No. 27, Jul 2020), the Vaccine Administration Law (Jun 2019), the Medical Device Supervision and Administration Regulation (State Council Decree 739, Jun 2021), and the Cosmetics Supervision and Administration Regulation (State Council Decree 727, Jan 2021), with hundreds of supporting NMPA orders + technical guidelines.

China became an ICH Regulatory Member in Jun 2017 + joined the ICH Management Committee in 2018 — a watershed alignment that accelerated the harmonisation of CDE clinical, CMC + e-submission expectations with ICH Q / S / E / M series guidelines. NMPA is an ICMRA member, an active IMDRF + APEC LSIF + WHO collaborator, and a long-standing PIC/S applicant + observer.

The 2019 Drug Administration Law + 2020 Drug Registration Regulation made the Marketing Authorisation Holder (MAH / 上市许可持有人) the central legal entity for drugs in China — analogous to the EU MAH + Japanese MAH. The MAH is the holder of the Drug Marketing Authorisation, takes life-cycle responsibility for quality + safety + efficacy, and may or may not be the manufacturer.

• MAH responsibilities — quality system, pharmacovigilance, post-market commitments, recall execution, manufacturing oversight whether in-house or contracted, ADR reporting, batch release + lot disposition.
• Domestic MAH — a Chinese-domiciled legal entity. Domestic MAH can directly hold the Drug Marketing Authorisation.
• Overseas MAH — a non-Chinese-domiciled MAH that holds the Drug Marketing Authorisation through the Imported Drug pathway + must designate a domestic Chinese agent of MAH (代理人) that performs Chinese-territory MAH functions including pharmacovigilance, complaints, agent for service of process, post-market surveillance + recalls.
• Manufacturing Authorisation — separate from the MAH. The Drug Manufacturing Licence (issued by provincial MPA or NMPA depending on category) authorises the site. MAH + manufacturer can be the same entity or different entities under contract.
• Contract Manufacturing — explicitly permitted for the MAH, with a written quality + commercial agreement + MAH responsibility for oversight + audit.
• Drug Marketing Authorisation Number (国药准字 H/Z/J/B/S) — H = chemical drugs, Z = traditional Chinese medicine, J = imported drugs, B = biologicals, S = biological products, with sub-letters for category.

Devices in China are regulated under the Medical Device Supervision and Administration Regulation (Decree 739, 2021) + the Regulations for Supervision and Administration of Medical Device Production / Operation, and CMDE-issued technical-review guidelines + classification catalogues.

• Class I — Lowest risk; provincial MPA Notification (备案); managed at provincial level.
• Class II — Moderate risk; provincial MPA Registration (注册) with NMPA-issued classification catalogue + technical-review reliance on national + provincial guidelines.
• Class III — Highest risk; NMPA / CMDE-level Registration (注册); the most demanding scientific review including clinical evaluation.
• IVDs — Class I / II / III with separate classification rules + a dedicated CMDE IVD review team.
• Type Testing — every device + IVD must pass Type Testing at an NMPA-recognised test laboratory (national or provincial) for safety + performance + EMC + biocompatibility per the applicable Chinese standards (GB / YY / industry standards). Test report + test scheme are core registration-dossier components.
• Clinical Evaluation — clinical evaluation report (CER) is required, with three routes per the 2021 update: exemption per the CMDE-published exemption catalogue, equivalence (comparison to a CMDE-approved equivalent device with full equivalence data), or clinical investigation (Chinese-local clinical trial + sometimes overseas-data acceptance under reliance).
• Imported Device Registration — non-Chinese manufacturer designates a Chinese agent of registrant for in-territory functions; the agent of registrant signs the Quality Agreement, handles registration submissions + post-market obligations.
• Type Testing for Imported devices — same Type Testing required, conducted at an NMPA-recognised Chinese laboratory; some categories accept overseas Type Testing with bridging.
• Innovative Device Pathway — CMDE-managed Innovative Medical Device pathway (创新医疗器械) for genuinely innovative devices with significant clinical benefit; reduced clock + intensive CMDE engagement.
• UDI — NMPA UDI implementation phased by risk class + product type since 2021; recognition of issuing agencies including GS1 + medical-device-specific issuing entities.
• Combination products — Drug-Device Combination Products regulated under a NMPA Order with primary-mode-of-action determination + lead-centre assignment (CDE or CMDE).

• Chinese GMP for Drugs — current version + the API Annex + Annex on Sterile Products + Annex on Biological Products + others; substantively aligned with ICH Q7 + WHO GMP + PIC/S GMP in most respects, with Chinese-specific elements (e.g. retention sample, lot-release controls, batch-record content).
• GMP for Medical Devices — NMPA Order No. 64 + Decree 739-derived requirements; substantively aligned with ISO 13485 + GHTF / IMDRF QMS principles.
• GCP for Drugs + Devices — 2020 GCP update aligned with ICH E6(R2) — major step in clinical-trial harmonisation.
• GLP for non-clinical safety — required for non-clinical safety studies supporting drug + device + biological approvals.
• CFDI — Center for Food and Drug Inspection is the operational inspection arm; CFDI inspectors conduct GMP, GCP, GLP, GVP + post-market inspections, both domestic + overseas (for Imported Drug + Imported Device manufacturers).
• Overseas inspections — CFDI conducts overseas inspections of foreign manufacturing sites supplying China, with a substantive uptick post-2018 reform; non-compliance can trigger Import Drug Licence (IDL) suspension or import ban.
• PIC/S — NMPA is a long-standing PIC/S applicant + observer; PIC/S accession is anticipated as Chinese inspectorate maturity continues to consolidate.
• Data integrity — CFDI Inspectorate enforces data-integrity expectations substantively aligned with PIC/S PI 041 + FDA + MHRA expectations.
• Inspection outcomes + remediation — observations classified by severity; deficiency response in formal CFDI procedures with public reporting + sanction for severe findings; criminal referral for cases of fraud / data falsification.

• GVP for Drugs — Good Pharmacovigilance Practice introduced 2021 (effective Dec 2021), substantively aligned with ICH E2A / E2D / E2E + EU GVP in many respects, requiring the MAH to establish a Chinese pharmacovigilance system.
• China National Center for ADR Monitoring (CCDRMA) — under NMPA; operates the national ADR + Adverse Device Event monitoring infrastructure.
• ICSR submission — E2B(R3)-aligned submission via the NMPA pharmacovigilance system; SUSARs within 15 calendar days, other categories with category-specific timelines.
• PSUR / PSAR — Periodic Safety Update Report / Periodic Safety Assessment Report; required for marketed drugs with NMPA-specified cycles.
• Risk Management — Risk Management Plan + risk-minimisation measures expectations growing under the GVP framework.
• Adverse Device Event Monitoring — for medical devices + IVDs, with provincial-level monitoring + national consolidation; serious incident reporting within stipulated timelines.
• Real-World Data + Real-World Evidence — China has a strongly developing RWD / RWE policy (Hainan Boao + Greater Bay Area pilots) for accelerating registration + post-market evidence generation.
• Recalls — Drug + Device Recall Administrative Measures govern classification (Level 1 / 2 / 3) + execution; CFDI + provincial MPA verify execution; severe recalls can be NMPA-mandated.
• Post-Market Reviews — Post-Approval Studies (PAS) for products under Priority + Conditional Approval; ongoing benefit-risk assessment.
• Re-Registration — Drug + Device Marketing Authorisations require periodic re-registration (typically every 5 years for drugs, 5 years for devices) — a significant lifecycle milestone with comprehensive review.

• ICH Regulatory Member since Jun 2017 + ICH Management Committee since 2018 — accelerated CDE alignment with ICH Q / S / E / M series; growing implementation across registration + post-market.
• ICMRA — NMPA is an active member contributing on pandemic preparedness, supply chain, AI / ML regulation, biosimilars.
• IMDRF — NMPA is an IMDRF member contributing on UDI, SaMD, AI / ML, QMS work products.
• WHO collaboration — NMPA is a WHO-listed authority + several Chinese vaccine manufacturers are WHO prequalified; cooperation on pandemic + vaccine + supply-chain issues.
• PIC/S — long-standing applicant + active observer; accession anticipated as inspectorate maturity continues to consolidate.
• Bilateral memoranda — NMPA holds active MoUs with FDA, EMA, Health Canada, MHRA, PMDA, TGA + others enabling information exchange + cooperation.
• Greater Bay Area + Hainan Boao pilot — special policy pilots permitting accelerated use of devices + drugs not yet NMPA-approved at designated medical institutions; pathway for real-world-evidence generation.
• Reliance + reference-product use — Imported Drug Registration + selected device pathways permit reliance + reference to FDA / EMA / Japan / Health Canada approval evidence with bridging requirements.
• Volume-Based Procurement (VBP) — while not a regulator-level reliance mechanism, VBP creates a strong de-facto link between consistency-evaluation passage + market access for generic drugs + selected devices; major commercial implications.

• Agent in China (代理人) misconfigured — Imported Drug / Device applicant doesn't have a properly designated Chinese agent of MAH / agent of registrant with the full legal + regulatory authorities.
• MAH responsibility gaps — domestic MAH that contracts manufacturing doesn't have demonstrable manufacturing-oversight + quality-agreement + audit programme acceptable to CFDI.
• Type Testing scheme gap — registration dossier submitted without complete Type Testing report covering applicable GB / YY / industry standards; CMDE returns the submission.
• Clinical Evaluation route misjudged — equivalence claimed without a CMDE-accepted equivalent device + full equivalence data; clinical investigation required.
• Imported Drug bridging insufficient — CDE requires Chinese-local clinical bridging that was not pre-planned in the global development program.
• Consistency Evaluation deferred — generic drug consistency-evaluation passage delayed → VBP exclusion + market-share loss.
• Chinese-language packaging / labelling / leaflet errors — Chinese-character labels not aligned with NMPA-approved version; insert leaflet missing required NMPA-approved content.
• Pharmacovigilance system not Chinese-domiciled — MAH operates only the global pharmacovigilance system without a Chinese-specific GVP-compliant infrastructure.
• CFDI overseas inspection deficiency — overseas API or finished-product site inspected by CFDI with critical / major observations; Import Drug Licence (IDL) suspended.
• Drug Master File (DMF) not properly linked — finished-product NDA references a DMF that hasn't been technically reviewed for the finished-product use.
• Re-Registration window missed — Drug Marketing Authorisation Number lapse + product withdrawal from the market until re-registration completes.
• Combination product PMA / primary-mode-of-action mis-classified — wrong centre (CDE vs CMDE) takes the lead → procedural restart.
• GVP risk-management measure not implemented — required risk-minimisation measure (HCP letter, registry, restricted distribution) not operational within NMPA-set deadline.
• Innovative Device pathway eligibility misjudged — CMDE doesn't grant innovative status; product reverts to standard pathway with longer clock.
• Provincial MPA jurisdiction errors — Class I device + Class I drug applications mis-routed between provincial MPA + NMPA; processing delays.

• CDE / CMDE pre-submission meeting count + commitment-incorporation rate before NDA / Imported Drug / device Registration.
• Implicit-approval clock metric (60 working days IND, 200 working days NDA standard etc) vs target by pathway.
• Priority Review / Breakthrough Therapy / Conditional Approval pathway utilisation rate + clock benefit.
• Consistency Evaluation passage rate + VBP eligibility position per generic chemical drug.
• DMF technical-review passage rate (A-file API, I-file excipient, Y-file packaging) per supplier.
• Type Testing first-pass passage rate per device / IVD.
• Clinical Evaluation route selection + CMDE acceptance per device.
• CFDI inspection outcome trend (domestic + overseas) per site.
• GVP ICSR + PSUR / PSAR on-time submission rate.
• Drug + Device recall classification + execution + verification timeline.
• Re-Registration window adherence per Marketing Authorisation.
• Chinese-language packaging / leaflet freshness + alignment with NMPA-approved version.
• Innovative Device pathway designation rate per pipeline.
• Greater Bay Area + Hainan Boao pilot utilisation where relevant.

V5 Ultimate runs the GMP + QMS + pharmacovigilance + technovigilance evidence layer underneath every NMPA-regulated activity. Specifically:

• Chinese GMP + Annex 11-equivalent control framework — computerised-systems lifecycle, electronic-record + electronic-signature controls aligned with ICH + CFDI expectations.
• CFDI inspection readiness — full document control, training, deviation, CAPA, change control, complaint, recall + post-market surveillance evidence pre-staged for CFDI domestic + overseas inspector requests, including data-integrity ALCOA+ controls.
• MAH + agent-in-China workflows — Chinese-domiciled MAH + agent-of-MAH structure encoded at workspace level, with role-based controls + e-sig routing for the MAH's lifecycle responsibilities.
• Manufacturing-oversight package — quality agreement + audit programme + change-control linkage + lot-release approval for contract-manufactured products under MAH oversight.
• DMF + ASMF packaging — drug master file content management for API + excipient + packaging submissions + finished-product NDA cross-reference + DMF holder + finished-product MAH coordination.
• Type Testing + Clinical Evaluation packaging — Type Testing report management + Clinical Evaluation route selection + equivalence-data assembly + Chinese local-trial integration.
• UDI lifecycle — NMPA UDI implementation tracking per device class + product type + the recognised issuing agencies; UDI database submission readiness.
• GVP + ICSR + PSUR — Chinese-domiciled pharmacovigilance system + SUSAR 15-day submission + PSUR / PSAR cycle management.
• Recall execution — Drug + Device Recall Administrative Measures classification (Level 1 / 2 / 3) workflows + provincial MPA + CFDI coordination.
• Re-Registration windows — Drug + Device Marketing Authorisation re-registration tracking with timed pre-renewal evidence assembly.
• Chinese-language localisation — Simplified Chinese label, leaflet, training + SOP packs with version control + NMPA-approved-version traceability.
• Audit trail + e-signature — 21 CFR Part 11-equivalent record-keeping for CFDI inspection use, including the Chinese electronic-signature law alignment.
• Greater Bay Area + Hainan Boao pilot evidence — pilot-specific evidence-collection for accelerated-access + real-world-evidence pathways.